Dual targeting by mTOR inhibitors and gefitinib in lung cancer as well as the demonstration of preclinical synergy between erlotinib and metformin in cell lines through a robust reduction of biomarkers represented by phosphorylated EGFR, AKT, ERK and S6 may pave the way for other drug associations (San Antonio Breast Cancer Conference 2010 Lau: A: PD03-05). This evidence concerns the gene EGFR and breast carcinoma.